Lead Sponsor

Sun Pharmaceutical Industries, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

•1. Healthy male or non-pregnant female aged ≥ 18 years with a clinical diagnosis of plaque psoriasis.
•2. Subjects must have provided IRB approved written informed consent.
•3. Subjects must have a clinical diagnosis of stable (at least 6 months) plaque psoriasis involving 3% to 20% body surface area (BSA), not including the face, scalp, groin, palms, fingernails, toenails, and soles in the BSA calculation.
•4. Subjects must have plaque psoriasis with a Physician's Global Assessment (PGA) score of 2 (mild), 3 (moderate), or 4 (severe)

•1. Female Subjects who are pregnant, nursing, or planning to become pregnant during study participation.
•2. Subjects with a known hypersensitivity to tapinarof or to any ingredients in the study drugs.
•3. Subjects with a current diagnosis of drug-induced psoriasis or unstable forms of psoriasis, including guttate, erythrodermic, exfoliative, or pustular psoriasis.
•4. Subjects with spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis as determined by the investigator.

Related studies

NCT07474792 · Plaque Psoriasis

NCT06979453 · Plaque Psoriasis

NCT07116967 · Plaque Psoriasis

NCT07250802 · Plaque Psoriasis

NCT07449702 · Plaque Psoriasis

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.